Hypomelanosis of Ito

Hypomelanosis of Ito (HOI) is a rare, sporadic neurocutaneous disorder characterized by hypopigmented streaks, whorls, or patches covering at least 2 body segments that follow the lines of Blaschko, the patterns of skin cell migration established during embryogenesis. These cutaneous findings are typically evident at birth or early childhood and are often asymmetric, sparing the mucous membranes, palms, and soles. HOI is understood to result from postzygotic somatic mutations, leading to chromosomal mosaicism, which causes impaired melanin production in some skin regions. This genetic mosaicism not only manifests in the skin but can also affect other organ systems, particularly the central nervous system, musculoskeletal structures, and eyes. Initial data obtained from neurology clinics suggest that the incidence of extracutaneous anomalies, especially neurological abnormalities, is exceptionally high. Further data from dermatology clinics reports a much lower incidence. Experts have refined the clinical terminology over time, and many suggest reserving the diagnosis of HOI for patients with both skin and extracutaneous manifestations. Patients with findings limited to the skin are diagnosed with linear nevoid hypopigmentation. The diagnosis is primarily clinical and based on recognizing characteristic cutaneous patterns and extracutaneous abnormalities, such as intellectual disability, epilepsy, hypotonia, scoliosis, limb asymmetry, strabismus, coloboma, and dental anomalies. Diagnostic support may include chromosomal analysis in selected cases, such as karyotyping of peripheral blood lymphocytes or genetic analysis of lesional skin fibroblasts. Because HOI is a form of pigmentary mosaicism, genetic testing may be normal in peripheral blood but reveal abnormalities in affected skin or other tissues. No curative treatment for HOI exists, and dermatologic therapy is generally unnecessary, though clinicians may recommend cosmetic camouflage for psychosocial concerns. Management is multidisciplinary, emphasizing early identification and intervention for associated extracutaneous findings. Ongoing follow-up should include surveillance for the development of new or evolving comorbidities. While the prognosis for cutaneous findings is generally benign, sometimes fading with age, the overall prognosis varies depending on the type and severity of systemic involvement. Early recognition and coordinated care are crucial for optimizing developmental outcomes, addressing complications, and supporting patients and their families throughout their lifespan.